Glenmark Pharma receives marketing rights in the US
Drug maker Glenmark Pharmaceuticals today said it has received marketing rights in the US for Azathioprine 50mg tablets, used to prevent kidney transplantation.
By PTI |
MUMBAI: Drug maker Glenmark Pharmaceuticals today said it has received marketing rights in the US for Azathioprine 50mg tablets, used to prevent kidney transplantation.
The company would market the drug through its US-based subsidiary Glenmark Generics, the company said in a filing to the Bombay Stock Exchange.
Azathioprine is the generic equivalent of Imuran tablets. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms, the filing added.
Glenmark is authorised to distribute 130 SKUs in the US. The company currently has 40 Abbreviated New Drug Application (ANDA) in various stages of approval process with US FDA, the filing added. Shares of the company were trading at Rs 306.90, down 2.66 per cent on the BSE.
The company would market the drug through its US-based subsidiary Glenmark Generics, the company said in a filing to the Bombay Stock Exchange.
Azathioprine is the generic equivalent of Imuran tablets. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms, the filing added.
Glenmark is authorised to distribute 130 SKUs in the US. The company currently has 40 Abbreviated New Drug Application (ANDA) in various stages of approval process with US FDA, the filing added. Shares of the company were trading at Rs 306.90, down 2.66 per cent on the BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
